Top

Published in:

01-03-2022 | Multiple Sclerosis | Letter to the Editor

HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis

Authors: Federico Montini, Bruno Colombo, Antonino Giordano, Ingazio Diego Lopez, Lucia Moiola, Vittorio Martinelli, Massimo Filippi

Published in: Neurological Sciences | Issue 3/2022

Excerpt

B cell-depleting therapies are considered highly effective in the treatment of relapsing multiple sclerosis. However they can cause immune system dysfunction, leading to increased risk of infection [1]. Apart from humoral immunity, B cells act as antigen-presenting cells and provoke T-Helper cell alterations. Ambulatory disability, prior immunosuppression, lymphopenia, and hypogammaglobulinemia are the most important risk factors for developing serious infection [1‐3], but even among normoglobulinemic patients treated with rituximab therapy, viral encephalitis should be considered when new neurological symptoms appear. A comprehensive long-lasting monitoring for infectious complications must be continuously performed [4]. …

Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I (2020) Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 7(9):1477–1487CrossRef

Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F (2021) Rituximab for the treatment of multiple sclerosis: a review. J Neurol. https://doi.org/10.1007/s00415-020-10362-z

Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169CrossRef

Epstein DJ, Dunn J, Deresinski S (2018) Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 5(8):ofy174CrossRef

Thong L, Plant BJ, McCarthy J, Murphy DM (2016) Herpetic tracheitis in association with rituximab therapy. Respirol Case Rep 4(4):e00158CrossRef

Baumer T, Fry C, Luppe S, Gunawardena H, Sieradzan K (2017) Human herpes virus-6 encephalitis causing severe anterograde amnesia associated with rituximab, azathioprine and prednisolone combination therapy for dermatomyositis. J Neurovirol 23(3):508–510CrossRef

Chotaliya KK, Gupta R, Marfatia YS (2015) Rituximab therapy in a case of pemphigus vulgaris triggering herpes simplex infection at varied sites. Indian Dermatol Online J 6(6):444–446CrossRef

Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47(2):187–198CrossRef

Cooper N, Arnold DM (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149(1):3–13CrossRef

10.

Novi G, Bovis F, Fabbri S, Tazza F, Gazzola P, Maietta I et al (2020) Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurol Neuroimmunol Neuroinflamm 7(5):e845

11.

Evertsson B, Hoyt T, Christensen A, Nimer FA, Foley J, Piehl F (2020) A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Mult Scler J Exp Transl Clin 6(4):2055217320964505PubMedPubMedCentral

Title: HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis
Authors: Federico Montini
Bruno Colombo
Antonino Giordano
Ingazio Diego Lopez
Lucia Moiola
Vittorio Martinelli
Massimo Filippi
Publication date: 01-03-2022
Publisher: Springer International Publishing
Keywords: Multiple Sclerosis
Rituximab
Encephalitis
Herpes Simplex Encephalitis
Rituximab
Published in: Neurological Sciences / Issue 3/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05803-0

At a glance: The STEP trials

Springer Medicine

HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2022

A novel homozygous mutation in TBK1 gene causing ALS-FTD

Sixth cranial nerve palsy after first intrathecal nusinersen administration

Time of symptoms beyond the bulbar region predicts survival in bulbar onset amyotrophic lateral sclerosis

Validity and reliability of the Turkish version of “the Dyspnea-ALS-Scale (DALS-15)”

Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19

Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?